CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 5 enrolled
Drug / intervention
BEMA Fentanyldrug
Likely dose
BEMA Fentanyl 1200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00696137
NCT00696137Phase 3Completed
CompareCT.gov

Open-label, Long-term Extension Study for Treatment of Breakthrough Cancer Pain With BEMA™ Fentanyl

BioDelivery Sciences International·interventional·Posted Jun 12, 2008·Updated Sep 24, 2019

In Brief

A Phase 3 clinical trial evaluating BEMA Fentanyl for Respiratory Depression. Completed, enrolled 5 participants.

Detailed Summary

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Depression
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 12, 2008
Enrollment StartJun 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.1 years ago

Interventions

BEMA Fentanyldrug

buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily